Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 6/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205851 | 0.91 | PTK2 (0.48) | PTK2JAK3LRRK2EGFRALK | |
| SCHEMBL10205540 | 0.90 | PTK2 (0.55) | PTK2LRRK2 | |
| SCHEMBL16255593 | 0.90 | PTK2 (0.53) | PTK2JAK3LRRK2EGFR | |
| SCHEMBL14331650 | 0.88 | PTK2 (0.48) | PTK2JAK3LRRK2EGFR | |
| SCHEMBL10205103 | 0.87 | EGFR (0.59) | PTK2EGFRALK | |
| SCHEMBL14331596 | 0.87 | PTK2 (0.53) | PTK2JAK3LRRK2 | |
| SCHEMBL10205101 | 0.86 | ALK (0.65) | PTK2JAK3EGFRALK | |
| SCHEMBL14331690 | 0.86 | ALK (0.55) | PTK2JAK3EGFRALK | |
| SCHEMBL14331701 | 0.86 | JAK3 (0.63) | PTK2JAK3EGFRALK | |
| SCHEMBL10205879 | 0.85 | EGFR (0.51) | PTK2EGFRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | PTK2 1524/4885JAK3 1636/4885LRRK2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.